The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors

In view of the therapeutic importance of dopamine D3 and D2 receptors, there remains considerable interest in novel ligands. Herein, we show that the tetrahydroisoquinoline 1H-indole-2-carboxylic acid {4-[2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-amide (SB269,652) behaves as an atypical, allosteric antagonist at D3 and D2 receptors. Accordingly, SB269,652 potently (low nanomolar range) abolished specific binding of [3H]nemanopride and [3H]spiperone to Chinese hamster ovary-transfected D3 receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D3 receptor-mediated activation of Gαi3 and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gαi3. SB269,652 (up to 10 μM) only weakly and partially (by approximately 20–30%) inhibited radioligand binding to D2 receptors. Likewise, SB269,652 only submaximally suppressed D2 receptor-mediated stimulation of Gαi3 and Gαqi5 (detected with the aequorin assay) and phosphorylation of ERK1/2 and Akt. Furthermore, SB269,652 only partially (35%) inhibited the dopamine-induced recruitment of β-arrestin2 to D2 receptors. Finally, Schild analysis using Gαi3 assays, and studies of radioligand association and dissociation kinetics, supported allosteric actions of SB269,652 at D3 and D2 receptors.

[1]  L. Luttrell,et al.  Diversity in arrestin function , 2009, Cellular and Molecular Life Sciences.

[2]  Willem Soudijn,et al.  Allosteric modulation of G-protein-coupled receptors , 2001 .

[3]  D. Sibley,et al.  Zinc modulates antagonist interactions with D2-like dopamine receptors through distinct molecular mechanisms. , 1999, The Journal of pharmacology and experimental therapeutics.

[4]  W. Im,et al.  Identification of transmembrane regions critical for ligand binding to the human D3 dopamine receptor using various D3/D1 transmembrane chimeras. , 1998, Molecular pharmacology.

[5]  E. Bézard,et al.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. , 2006, CNS & neurological disorders drug targets.

[6]  J. Seamans,et al.  Dopamine Receptor Signaling , 2004, Journal of receptor and signal transduction research.

[7]  R. Gainetdinov,et al.  Akt/GSK3 signaling in the action of psychotropic drugs. , 2009, Annual review of pharmacology and toxicology.

[8]  R. Hen,et al.  G(olf)alpha mediates dopamine D1 receptor signaling. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  R. Mishra,et al.  Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of l-prolyl-l-leucyl-glycinamide , 1996, Brain Research.

[10]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[11]  B. Cullen.  Use of eukaryotic expression technology in the functional analysis of cloned genes. , 1987, Methods in enzymology.

[12]  H. Niznik,et al.  Modulation of Agonist Binding to Human Dopamine Receptor Subtypes by l-Prolyl-l-leucyl-glycinamide and a Peptidomimetic Analog , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[14]  Leonardo Belluscio,et al.  GOLFα Mediates Dopamine D1 Receptor Signaling , 2000, The Journal of Neuroscience.

[15]  S. Lazareno,et al.  Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. , 1995, Molecular pharmacology.

[16]  M. Millan,et al.  Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole , 2003, Journal of neurochemistry.

[17]  S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : II . Functional and Behavioral Profile Compared with GR 218 , 231 and L 741 , 626 , 2000 .

[18]  Lei Shi,et al.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[20]  K. Mohr,et al.  Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.

[21]  T. Kenakin,et al.  G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.

[22]  S. Kapur,et al.  The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[23]  M. Caron,et al.  A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation* , 1997, The Journal of Biological Chemistry.

[24]  M. Millan,et al.  S 33084 , a Novel , Potent , Selective , and Competitive Antagonist at Dopamine D 3-Receptors : I . Receptorial , Electrophysiological and Neurochemical Profile Compared with GR 218 , 231 and L 741 , 626 , 2000 .

[25]  M. Millan,et al.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats , 2004, Psychopharmacology.

[26]  J. Rung,et al.  Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization , 2008, Journal of Neural Transmission.

[27]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[28]  M. Okuda,et al.  [Dopamine receptor]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[29]  J. Hagan,et al.  SB-269652 is a selective D3 receptor antagonist in vitro and in vivo , 1999, European Neuropsychopharmacology.

[30]  M. Millan,et al.  S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with Ropinirole , 2004, Journal of Pharmacology and Experimental Therapeutics.

[31]  C. Tamminga,et al.  Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. , 2002, Current drug targets. CNS and neurological disorders.

[32]  G Vassart,et al.  Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity* , 1999, The Journal of Biological Chemistry.

[33]  M. Millan,et al.  G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. , 1999, Molecular pharmacology.

[34]  M. Millan,et al.  Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. , 1999, Molecular pharmacology.

[35]  S. Hoare,et al.  Regulation of D2 dopamine receptors by amiloride and amiloride analogs. , 1996, Molecular pharmacology.

[36]  B. Conklin,et al.  Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. , 1993, Nature.

[37]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  Irina S. Moreira,et al.  Allosteric communication between protomers of dopamine Class A GPCR dimers modulates activation , 2009, Nature chemical biology.

[39]  M. Millan,et al.  S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.

[40]  F. Ehlert,et al.  Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.

[41]  R. Lefkowitz,et al.  β-Arrestins and Cell Signaling , 2007 .

[42]  M. Millan,et al.  S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[43]  B. Conklin,et al.  Substitution of three amino acids switches receptor specificity of Gqα to that of Giα , 1993, Nature.

[44]  S. Lazareno,et al.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.

[45]  B. Levant,et al.  Signaling Mechanisms of the D3 Dopamine Receptor , 2004, Journal of receptor and signal transduction research.

[46]  M. Caron,et al.  Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated Kinase* , 2004, Journal of Biological Chemistry.

[47]  J. Schetz.  Allosteric modulation of dopamine receptors. , 2005, Mini reviews in medicinal chemistry.